Renova Therapeutics Prioritizes Gene Therapy Development for Heart Failure and Type 2 Diabetes

Renova Therapeutics, based in Carlsbad, California, has announced a strategic focus on advancing its gene therapies, RT-100 and RT-200, for heart failure and type 2 diabetes respectively. The company is gearing up to launch pivotal human trials in these areas under two major regulatory pathways in the U.S. and UK.

RT-100, targeting heart failure, has already shown promise in phase 2 trials and harbors FDA Fast Track designation. Planned phase 2b/3 trials in the U.S aim to validate its effectiveness further, potentially advancing it to phase 3. Heart failure globally affects over 64 million individuals, emphasizing the critical importance of advancing effective treatments.

Concurrently, RT-200 is poised to undergo initial human trials in the UK under the Innovative Licensing and Access Pathway (ILAP), following promising preclinical results. With over 537 million people worldwide suffering from type 2 diabetes, the need for innovative treatments like RT-200 is urgent.

The company’s defined roadmap for these therapies underscores its commitment to tackling some of the most challenging chronic diseases by leveraging advanced genetic medicine solutions.